TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04703114

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab
Description: Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva samples
Description: Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva samples
Description: Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Faeces samples
Description: Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Faeces samples
Description: Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic blood collection
Description: Collection to further research at each visit

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic blood collection
Description: Collection to further research at each visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Demographics, symptoms, biological constants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Demographics, symptoms, biological constants
Study: NCT06427811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Film-coated tablets with 40 mg dose strength taken orally
Study: NCT05455502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablet for oral administration.
Study: NCT06200883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral vial
Description: In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline Bitartrate
Description: In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
Study: NCT05994079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity focused ultrasound
Description: Parameters:~Transducer frequency 7-2-mhz 1.5-9.0-mm focal depth. The pulse duration for each individual exposure ranged from 25 to 40 milliseconds.~Energy per ultrasound pulse ranged from 1.0 to 1.5 J

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical firming creams
Description: medical topical firming creams
Study: NCT05884944

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham- Light touch, not reaching restrictive barrier
Description: Sham- Light touch, not reaching restrictive barrier For the control group, the subjects hip, knee, and ankle joints will be moved bilaterally 3 times into each plane to mimic the OMM muscle energy treatment. The joint will be moved in each plane of motion without reaching the joint barrier. The hip joint will be moved into adduction, extension, and flexion, the knee joint will be moved into extension and flexion, and the ankle will be moved into plantarflexion and dorsiflexion 3 times in each direction without reaching the barrier passively.
Study: NCT05796271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-Chop and Roflumilast
Description: All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
Study: NCT06562881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduling Navigation
Description: Participants will be connected to a scheduler to schedule a surgical consultation visit at time of recruitment. Participation does not guarantee or require surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without Scheduling Navigation
Description: Patients will work with clinic staff in the usual fashion for their treatment for primary hyperparathyroidism. They will not be connected directly to a scheduler to help schedule a surgical consultation visit at time of recruitment. With our crossover design, if patients have not yet received surgical consultation after 3 months, they will be called and connected with a scheduler at that time. Participation does not guarantee or require surgery.
Study: NCT05902572

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only.

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only.

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only.
Study: NCT05482958

Intervention type: DEVICE
Intervention: HOP watch
Description: Prospective observational study

Intervention type: DEVICE
Intervention: HOP watch
Description: Prospective observational study
Study: NCT05261321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis oil with a high ratio of THC to CBD
Description: In the first active condition, cannabis oil with a high THC to CBD ratio will be administered to participants.
Study: NCT05653817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrilizumab
Description: Carrilizumab 200mg Q3W d1
Study: NCT05902572

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only.
Study: NCT05261321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis oil with a high ratio of CBD to THC
Description: In the second active condition, cannabis oil with a high CBD to THC ratio will be administered to participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control condition, the placebo will be administered to participants.
Study: NCT05653817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Albumin-bound paclitaxel 125 mg/m2 d1,8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib mesylate tablets for treatment: 250mg
Study: NCT05663957

Intervention type: DRUG
Intervention: Evusheld
Description: EVUSHELD users
Study: NCT06416410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 administered orally as a tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 administered orally as a tablet or capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered as an intravenous (IV) infusion
Study: NCT06010264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: In the kinesiotaping group, kinesiotape was applied from the first postoperative day in addition to conservative treatment.~Kinesiobant application was performed regularly until the 6th week by a researcher with a certificate in kinesiobanting in accordance with the lymphatic correction and pain inhibition techniques described by Kenzo Kase.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Shamtape
Description: In the sham taping group, sham tape was applied from the first postoperative day in addition to conservative treatment. Medical flasters were used as sham tape. Sham tapes were applied by cutting in the same fan shape as in kinesioband.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Program
Description: Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain
Study: NCT05834348

Intervention type: DRUG
Intervention: lorlatinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: crizotinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: brigatinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: ceritinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: alectinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: atezolizumab
Description: As provided in real world practice

Intervention type: DRUG
Intervention: bevacizumab
Description: As provided in real world practice

Intervention type: DRUG
Intervention: paclitaxel
Description: As provided in real world practice

Intervention type: DRUG
Intervention: carboplatin
Description: As provided in real world practice

Intervention type: DRUG
Intervention: docetaxel
Description: As provided in real world practice

Intervention type: DRUG
Intervention: erlotinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: gefitinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: afatinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: dacomitinib
Description: As provided in real world practice

Intervention type: DRUG
Intervention: osimertinib
Description: As provided in real world practice
Study: NCT06299774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency care at home
Description: A mobile integrated health paramedic under the direction of a remote emergency care physician will arrive at the patient's home and deliver emergency care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emergency care at a brick-and-mortar emergency department
Description: Standard emergency care delivered in a brick-and-mortar emergency department.
Study: NCT05834348

Intervention type: DRUG
Intervention: pembrolizumab
Description: As provided in real world practice

Intervention type: DRUG
Intervention: nivolumab
Description: As provided in real world practice

Intervention type: DRUG
Intervention: entrectinib
Description: As provided in real world practice
Study: NCT06366230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea in the dialysate
Description: Adding urea to the dialysis fluid. Ure-Na 15 grams would be used. It would be added to the acid component of the dialysis fluid. The amount added would depend on the serum BUN concentration and is determined by a simple calculation. It would be available in powder form. Urea would be added just to the first 1-3 dialysis treatments as needed.
Study: NCT05065450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial Stimulation
Description: Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
Study: NCT05115513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium THC
Description: Marijuana flower with medium THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo THC
Description: Marijuana flower with no THC
Study: NCT06368934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sub-lobectomy
Description: Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: imaging total resection
Description: Imaging total resection (T1-enhanced borders) will met the RANO criteria
Study: NCT02742311

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic disectomy
Description: Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic disectomy
Description: Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
Study: NCT05283187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy Group
Description: Mindfulness Based Cognitive Therapy
Study: NCT05664802

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Description: A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Description: A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
Study: NCT05329870

Intervention type: OTHER
Intervention: SNP array
Description: SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT

Intervention type: OTHER
Intervention: SNP array
Description: SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
Study: NCT05954429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serplulimab
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
Study: NCT05839704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae Plane Block
Description: Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Wall Blocks
Description: Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
Study: NCT05375214

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)
Description: Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
Study: NCT05095857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine
Description: S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline (placebo)
Description: Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
Study: NCT05675228

Intervention type: OTHER
Intervention: data collection
Description: Knowledge about genital herpes
Study: NCT05351697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR105 injection
Description: 0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
Study: NCT04611763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil preoperatively
Description: give Flurbiprofen axetil 15 min before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen axetil postoperatively
Description: give Flurbiprofen axetil at the end of surgery
Study: NCT05862532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TeTrimTeas welsh Herbal tea with rhubarb root
Description: TeTrimTeas welsh Herbal tea with green tea and rhubarb root
Study: NCT00013169

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Strong Patient Focus
Study: NCT05862532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TeTrimTeas welsh Herbal tea with senna
Description: TeTrimTeas welsh Herbal tea with green tea and senna
Study: NCT05633966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 112-121
Description: SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
Study: NCT05580068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypertension therapy through iATROS medical device
Description: The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better.
Study: NCT04882787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTE hearing aid
Description: Amplification
Study: NCT06056856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penile skin graft substituttion urethroplasty
Description: substitution of long anterior urethral strictures using one-sided dorsal perineal approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Mucosal Graft substitution urethroplasty
Description: substitution of long anterior urethral strictures using one-sided dorsal perineal approach
Study: NCT06033872

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Focused education, medication adjustment and telemonitoring
Description: 1. Focused diabetes education session for Ramadan fasting~   Participants will be taught to record~  1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~3. Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software.
Study: NCT06412913

Intervention type: DEVICE
Intervention: MJ-Flex The New Metaizeau Nail
Description: Intramedullary implantation of the MJ-Flex elastic nail in long bones to provide bone fixation
Study: NCT05862532

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TeTrimTeas welsh Herbal tea with green tea
Description: TeTrimTeas welsh Herbal tea with green tea
Study: NCT06134479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5
Description: On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
Description: On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
Study: NCT04982276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK109
Description: Subjects will receive AK109 by intravenous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK109
Description: Subjects will receive AK109 by intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Subjects will receive AK109 in combination with paclitaxel.